Sus Clinicals, Inc. published a manuscript comparing other AI tools to Oncoscopes living library.
Public source
Publisher name
Public post
https://lnkd.in/dcCf8_hu I am excited to share our manuscript is out! A thanks to my co-authors, among the leaders in the field. H. Rugo ∙ A. Forsythe ∙ D. Flora ∙ S. Gl…
Company
Sus Clinicals, Inc.
Enabling our healthcare client partners to accelerate breakthrough cancer solutions.
- Industry
- Research Services
- Location
- Cincinnati, US
- Company size
- 11–50 employees
About Sus Clinicals, Inc.
Sus Clinicals solves major problems in qualifying new cancer drugs, devices, diagnostics and therapies. Using a proprietary model of testing on genetically-modified pigs pioneered at the University of Illinois, Sus Clinicals leverages the inherent advantages of a patent-pending large animal testing methodology combined with novel clinical approaches to reduce false positives, model the interactions of multiple diseases, and accelerate progress toward human trials for the most promising therapies.
See moreLatest activity
Latest activity from Sus Clinicals, Inc.
3 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Oncoscope
Oncoscope published a manuscript evaluating the Living Oncology Evidence Platform using real oncology treatment scenarios and comparing its performance with leading AI tools including OpenEvidence, Perplexity, and Consensus.
Research & Knowledge
The Netherlands Cancer Institute
The Netherlands Cancer Institute published a peer-reviewed paper showing that a model trained on participants' data is as good as trained with pathologists’ annotations.
Research & Knowledge
IU Simon Comprehensive Cancer Center
IU Simon Comprehensive Cancer Center published a new article in Radiology titled Artificial Intelligence by Spyridon Bakas, PhD, and colleagues.
Research & Knowledge
iOMEDICO
iOMEDICO published the final results of the REALTRK registry on rare NTRK fusion-positive cancers in JCO Precision Oncology, including 47 adults with advanced solid tumors and 26 patients who received TRK inhibitor therapy.
Research & Knowledge
Break Through Cancer